Previous 10 | Next 10 |
home / stock / akblf / akblf news
The Lancet Regional Health - Europe publishes 'real-world evidence' from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma - Results from ALK-sponsored REACT (REAl-world effeCTtiveness of allergy immunotherapy) study have ...
ALK-Abelló A/S (OTCPK:AKBLF): Q2 Operating profit was at DKK 48M Revenue of DKK 866M Press Release For further details see: ALK-Abelló A/S reports Q2 results
ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients - Acquisition Supports ALK's Commitment to Provide Innovative Solutions to Address the Needs of Healthcare Providers, Including ENTs, and their Patien...
U.S. FDA Approves ALK's RAGWITEK® (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use as Immunotherapy for Children and Adolescents With Short Ragweed Pollen-Induced Allergic Rhinitis With or Without Conjunctivitis - RAGWITEK is now indicated to treat ragweed ...
ALK-Abelló A/S (AKBLF): Q3 GAAP EPS of DKK1.8Revenue of DKK772M (+4.4% Y/Y)Press Release For further details see: ALK-Abelló A/S reports Q3 results
Actress and Entrepreneur JoAnna Garcia Swisher and Husband, Former MLB World Champion Nick Swisher, Join New Campaign to Empower Allergy Sufferers to Take Control of Their Allergies - New survey results reveal 71 percent of U.S. adults have experienced environmental allergy symp...
ROUND ROCK, Texas , June 17, 2020 /PRNewswire/ -- ALK ( ALKB:DC / OMX:ALK B / AKABY / AKBLF ) a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies, announced today the signing of an exclusive agreement with Otonomy...
ALK-Abelló A/S ( OTCPK:AKBLF ): FY GAAP EPS of -DKK4.60. More news on: ALK-Abelló A/S, ALK-Abelló A/S, Earnings news and commentary, Healthcare stocks news, Read more ...
ROUND ROCK, Texas , Nov. 8, 2019 /PRNewswire/ -- ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ), a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies, announced new Phase 3 data today on its sublingual allergy immunothera...
ROUND ROCK, Texas , Sept. 28, 2019 /PRNewswire/ -- ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) is pleased to join several organizations as a sponsor of the third annual National Penicillin Allergy Day, an awareness day to help educate the community on penicillin allergies and t...
News, Short Squeeze, Breakout and More Instantly...
Alk-Abello A/S Company Name:
AKBLF Stock Symbol:
OTCMKTS Market:
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) today announced that the Board of Directors has adopted a new corporate strategy (Allergy + ) and 2028 financial ambitions. Allergy + aims to further strengthen ALK’s leadership in allergy immunotherapy, establishing a leading position...
Company release No. 11/2024 ALK delivers 10 % organic revenue growth with operating profit up 41 % in Q1 and upgrades outlook The growth in ALK's overall sales was primarily driven by the European tablet sales, which were boosted by the inflow of new patients and improved ...
ALK ( ALKB:DC / OMX: ALK B / AKBLF ): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 14 March 2024 at 4:00 PM (CET) at ALK-Abelló A/S, 1 Bøge Allé, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the B...